Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

601. An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings

in the reduction of relapse in schizophrenic patients. 2. To perform a meta-analysis of the research findings by pooling data from the selected trials to improve estimates of effect size. Searching MEDLINE was searched from 1966 to July 1992, for previous reviews using the MeSH terms 'family' and 'schizophrenia' combined with textword plus abstract search 'review', and for primary studies using the terms 'schizophrenia' and 'family therapy'. Material published in the English, French, Spanish, Italian (...) ; Recurrence; Schizophrenia /rehabilitation; Schizophrenic Psychology; Treatment Outcome AccessionNumber 11996008005 Date bibliographic record published 31/07/1996 Date abstract record published 31/07/1996 Record Status This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results and conclusions followed by a detailed critical assessment on the reliability of the review and the conclusions

1994 DARE.

602. Schizophrenia, Consensus statement

Schizophrenia, Consensus statement Schizophrenia, Consensus statement Schizophrenia, Consensus statement The Danish Medical Research Council and the Danish Hospital Institute Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation The Danish Medical Research Council and the Danish Hospital Institute. Schizophrenia, Consensus statement. Danish (...) Institute for Health Services Research (DSI). 1993 Authors' objectives To provide an overview of activities and problems concerning schizophrenia, and thereby forward the diffusion of expert knowledge to the public. Authors' conclusions There is a need for further coordination of the psychiatric, the psychologic, and the social efforts. There is also a need for an increase in research, development and education. Other output or dissemination activity: Impact not evaluated. Project page URL Indexing

1993 Health Technology Assessment (HTA) Database.

603. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. Full Text available with Trip Pro

Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. To evaluate a novel approach to the prophylaxis of schizophrenic relapse characterised by administration of brief courses of neuroleptic for the earliest non-psychotic signs of relapse (prodromal symptoms).Two year follow up of subjects randomised, double blind, to receive either active (control group) or placebo (intermittent group) depot neuroleptic medication (...) . Both groups received brief courses of oral neuroleptic when prodromal symptoms or relapse occurred.Psychiatric outpatient department, Charing Cross Hospital, London.54 Stable patients in remission who met the American Psychiatric Association's DSM-III criteria for schizophrenia on the basis of case notes.Survival without relapse, survival without hospitalisation, point prevalence of extrapyramidal side effects and tardive dyskinesia, structured assessment of social functioning (social adjustment

1990 BMJ Controlled trial quality: uncertain

604. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. Full Text available with Trip Pro

for schizophrenia were randomised double blind to receive brief intermittent treatment with either active or placebo depot neuroleptic injections. Only three patients given placebo injections and two controls were admitted to hospital during one year of follow up. Eight (30%) of the patients given placebo injections and only 2 (7%) of the controls, however, had a recurrence of schizophrenic symptoms. Patients given placebo injections experienced fewer extrapyramidal side effects and showed a trend towards (...) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. A study was conducted to investigate a novel approach to the prophylaxis of schizophrenic relapse. The treatment strategy comprised brief intermittent courses of neuroleptic agents begun as soon as non-psychotic symptoms believed to be early signs of relapse appeared. Fifty four stable, remitted outpatients meeting the American Psychiatric Association's DSM-III criteria

1989 BMJ Controlled trial quality: uncertain

605. PARTIAL TRISOMY CHROMOSOME 5 COSEGREGATING WITH SCHIZOPHRENIA Full Text available with Trip Pro

PARTIAL TRISOMY CHROMOSOME 5 COSEGREGATING WITH SCHIZOPHRENIA Schizophrenia was associated with a distinct autosomal abnormality in two related mildly dysmorphic individuals. The finding of cosegregation of schizophrenia and a partial trisomy of chromosome 5 in the family suggests a potential location of a gene or genes linked to schizophrenia.

1988 Lancet

606. The therapeutic efficacy of hemodialysis in schizophrenia. (Abstract)

The therapeutic efficacy of hemodialysis in schizophrenia. Prompted by previous reports of substantial clinical improvement in most schizophrenic patients given hemodialysis for their psychiatric condition, we studied the efficacy of hemodialysis in 15 schizophrenic outpatients, under double-blind, controlled conditions. The patients were randomly assigned to either a real-sham or sham-real sequence of dialysis treatment. Results of repeated measurement and other analyses of data on symptoms (...) and behavior that were collected before study treatment, at crossover, and at the end of treatment revealed no difference between the effects of real and sham dialysis. These results provide important experimental evidence of the lack of therapeutic efficacy of hemodialysis in schizophrenia.

1983 NEJM Controlled trial quality: uncertain

607. Family management in the prevention of exacerbations of schizophrenia: a controlled study. (Abstract)

Family management in the prevention of exacerbations of schizophrenia: a controlled study. Environmental stress has been implicated as an important factor in the relapse of schizophrenic patients receiving optimal drug therapy. In a randomized controlled study, we compared at-home family therapy with clinic-based individual supportive care in the community management of schizophrenia in 36 patients taking neuroleptic maintenance medications. The family-treatment approach sought to enhance (...) in the hospital, as compared with 8.39 days for the comparison group. Significantly lower levels of schizophrenic symptomatology on blind rating-scale assessments supported these clinical observations of the superiority of family management.

1982 NEJM Controlled trial quality: uncertain

608. ECT for schizophrenia. (Abstract)

ECT for schizophrenia. Electroconvulsive therapy (ECT) in the treatment of schizophrenia was evaluated in a double-blind trial; the clinical change after ECT was compared with that after a treatment procedure identical to it but for two exceptions--no electricity was used and no convulsion was induced. All patients had paranoid schizophrenia according to Present State Examination criteria and all received standard doses of neuroleptics for at least 2 weeks before random assignment to the two

1980 Lancet Controlled trial quality: uncertain

609. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. (Abstract)

. It was as great in patients with evidence of deterioration (Feighner-positive patients) as in patients without deterioration and was less in patients who had affective disturbance in addition to schizophrenia symptoms. The findings are consistent with the hypothesis that dopamine-receptor blockade is the only requirement for antipsychotic activity and suggest that the antipsychotic effect occurs in patients with typically schizophrenic illnesses but may be limited to positive symptoms. (...) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. In a double-blind trial in which 45 patients with acute schizophrenia took part the alpha-isomer of flupenthixol (which blocks the dopamine receptor) was found to be significantly more effective than both beta-flupenthixol (which does not) and placebo. The drug effect was confined to the "positive" symptoms--delusions, hallucinations, and though disorder--and appeared only in the 3rd and 4th weeks of the trial

1978 Lancet

610. Propranolol as an adjunct to the treatment of schizophrenia. (Abstract)

Propranolol as an adjunct to the treatment of schizophrenia. Propranolol contributed usefully to the practical management of patients with chronic schizophrenia whose florid symptoms had not remitted with major tranquillisers. 14 patients who had received an average equivalent of 954 mg per day of chlorpromazine for 10 years were given, in addition, either propranolol or a placebo for 12 weeks. Both groups had improved by the twelfth week, but the propranolol group had improved significantly

1977 Lancet Controlled trial quality: uncertain

611. Editorial: Dietary factors and schizophrenia. (Abstract)

Editorial: Dietary factors and schizophrenia. 937890 1976 08 23 2004 11 17 0003-4819 84 6 1976 Jun Annals of internal medicine Ann. Intern. Med. Editorial: Dietary factors and schizophrenia. 745 Kety S S SS eng Clinical Trial Journal Article Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 AIM IM Diet adverse effects Humans Schizophrenia diet therapy etiology 1976 6 1 1976 6 1 0 1 1976 6 1 0 0 ppublish 937890

1976 Annals of Internal Medicine Controlled trial quality: uncertain